Related Experiment Video
Updated: Feb 26, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.6K
Guidelines on the Use of Methotrexate in Psoriasis
G Carretero1, L Puig2, L Dehesa1
1Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, España.
Actas Dermo-Sifiliograficas
|July 16, 2017
Summary
Methotrexate remains a valuable treatment for psoriasis, offering effective symptom control alone or with other therapies. Guidelines are provided for its safe and appropriate use in managing this chronic inflammatory skin condition.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Psoriasis is a chronic, multifactorial inflammatory disease affecting 1.5% of the Spanish population, significantly impacting quality of life.
- Current treatments include traditional systemic therapies and newer biologic agents, expanding therapeutic options for severe cases.
Purpose of the Study:
- To establish the role of methotrexate in psoriasis treatment.
- To develop consensus guidelines for the safe and effective use of methotrexate in psoriasis management.
Main Methods:
- Consensus development among members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology.
- Review of existing systemic treatments and biologics for psoriasis.
Main Results:
- Methotrexate is a classic antipsoriatic drug still useful as monotherapy or in combination with other systemic drugs.
- Methotrexate can be used as rescue therapy or in combination with biologics for improved psoriasis control.
Conclusions:
- Methotrexate plays a significant role in the therapeutic armamentarium for psoriasis.
- Guidelines are essential for ensuring the safe and proper use of methotrexate in managing psoriasis.
More Related Videos
Related Concept Videos
01:29Therapeutic Drug Monitoring: Affecting Factors
286
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
286
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
604
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
604
01:17Phase II Reactions: Methylation Reactions
813
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
813
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
51
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
51
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
652
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
652
01:26Psychosis: Goals of Pharmacotherapy
641
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
641